{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:51:46Z","timestamp":1771861906168,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030831","name":"Novartis Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jjcc.2025.05.020","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:08:10Z","timestamp":1748862490000},"page":"92-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety of sacubitril\/valsartan in Japanese patients with chronic heart failure: A post-marketing surveillance study"],"prefix":"10.1016","volume":"87","author":[{"given":"Jiro","family":"Arita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Sasajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yarimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2025.05.020_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116232","article-title":"Challenging and target-based shifting strategies for heart failure treatment: an update from the last decades","volume":"224","author":"Hattori","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2025.05.020_bb0010","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.ihj.2018.01.002","article-title":"Sacubitril\/valsartan: a novel angiotensin receptor-neprilysin inhibitor","volume":"70","author":"Dargad","year":"2018","journal-title":"Indian Heart J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0015","doi-asserted-by":"crossref","first-page":"9j","DOI":"10.1016\/S0002-9149(97)00832-1","article-title":"The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease","volume":"80","author":"Cody","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0025","author":"PMDA"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jjcc.2016.11.011","article-title":"Efficacy and safety of sacubitril\/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: rationale for and design of the randomized, double-blind PARALLEL-HF study","volume":"70","author":"Tsutsui","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0035","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - results from the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0040","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1253\/circj.CJ-18-0939","article-title":"PARALLEL-HF - a paradigm shift for heart failure treatment in Japan?","volume":"82","author":"Min","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0045","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jjcc.2023.11.005","article-title":"Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF registry","volume":"84","author":"Matsumoto","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0055","author":"(europa.eu) LEERvps"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1253\/circj.CJ-23-0349","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with heart failure according to baseline systolic blood pressure - results from a subgroup analysis of the PARALLEL-HF Study","volume":"88","author":"Tsutsui","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1253\/circj.CJ-23-0174","article-title":"Long-term treatment with sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - open-label extension of the PARALLEL-HF study","volume":"88","author":"Tsutsui","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0070","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1253\/circj.CJ-17-1424","article-title":"Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction - baseline characteristics and treatment of PARALLEL-HF trial","volume":"82","author":"Tsutsui","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0075","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0080","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0085","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0090","doi-asserted-by":"crossref","first-page":"9095","DOI":"10.1038\/s41598-024-60011-y","article-title":"Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan","volume":"14","author":"Okami","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0095","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212","article-title":"Effects of sacubitril\/valsartan in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to background therapy","volume":"9","author":"Okumura","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0105","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of sacubitril\/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0115","author":"Japanese Heart Failure Society"},{"key":"10.1016\/j.jjcc.2025.05.020_bb0120","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-20-0947","article-title":"Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF)","volume":"85","author":"Ide","year":"2021","journal-title":"Circ J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:40:31Z","timestamp":1767800431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508725001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0914508725001443"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.05.020","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety of sacubitril\/valsartan in Japanese patients with chronic heart failure: A post-marketing surveillance study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}